Synova to market ovulation test:
This article was originally published in Clinica
Media, Pennsylvania-based provider of noninvasive diagnostic tests Synova Healthcare has gained exclusive North American distribution rights for an ovulation test designed to track a woman's ovulation cycle and, thereby, increase the likelihood of her becoming pregnant. Unlike conventional ovulation kits that use urine samples, this test, developed by Ovulation Tester, uses saliva as a testing medium. The product is already cleared by the FDA and is pending Canadian approval.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.